Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.

We evaluated factors associated with normalization of the absolute CD4+ T-cell counts, per cent CD4+ T cells and CD4+/CD8+ T-cell ratio. A multicentre observational study was carried out in patients with sustained HIV-RNA <50 copies/mL. Outcomes were: CD4-count >500/mm(3) and multiple T-cell marker recovery (MTMR), defined as CD4+ T cells >500/mm(3) plus%CD4 T cells >29%plus CD4+/CD8+ T-cell ratio >1. Kaplan-Meier survival analysis and Cox regression analyses to predict odds for achieving outcomes were performed. Three hundred and fifty-two patients were included and followed-up for a median of 4.1 (IQR 2.1-5.9) years, 270 (76.7%) achieving a CD4+ T-cell count >500 cells/mm(3) and 197 (56%) achieving MTMR. Using three separate Cox models for both outcomes we demonstrated that independent predictors were: both absolute CD4+ and CD8+ T-cell counts, %CD4+ T cells, a higher CD4+/CD8+ T-cell ratio, and age. A likelihood-ratio test showed significant improvements in fitness for the prediction of either CD4+ >500/mm(3) or MTMR by multivariable analysis when the other immune markers at baseline, besides the absolute CD4+ count alone, were considered. In addition to baseline absolute CD4+ T-cell counts, pretreatment %CD4+ T cells and the CD4+/CD8+ T-cell ratio influence recovery of T-cell markers, and their consideration should influence the decision to start antiretroviral therapy. However, owing to the small sample size, further studies are needed to confirm these results in relation to clinical endpoints.

[1]  V. Soriano,et al.  Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides , 2002, AIDS.

[2]  Peter Hunt,et al.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.

[3]  S. Moreno,et al.  Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Shaffer.  Multiple Hypothesis Testing , 1995 .

[5]  Robert Tibshirani,et al.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.

[6]  Ryung S. Kim,et al.  Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease , 2002, AIDS.

[7]  J. Margolick,et al.  Failure of T-cell homeostasis preceding AIDS in HIV-1 infection , 1995, Nature Medicine.

[8]  R. Kuchenbecker,et al.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. , 2011, Annals of internal medicine.

[9]  J. Margolick,et al.  Increase and Plateau of CD4 T‐Cell Counts in the 3½ Years After Initiation of Potent Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[10]  E. Graviss,et al.  Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. Katlama,et al.  HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.

[12]  JD Lundgren,et al.  Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study , 2007, The Lancet.

[13]  M. Hirsch,et al.  Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384 , 2006, Journal of acquired immune deficiency syndromes.

[14]  D. Costagliola,et al.  Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. , 2010, Archives of internal medicine.

[15]  A. Phillips,et al.  The role of HIV in serious diseases other than AIDS , 2008, AIDS.

[16]  E. Seminari,et al.  Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy , 2010, Antiviral therapy.

[17]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[18]  A. Telenti,et al.  CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. , 2003, Archives of internal medicine.

[19]  Klaus Nordhausen,et al.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction, Second Edition by Trevor Hastie, Robert Tibshirani, Jerome Friedman , 2009 .

[20]  B. Clotet,et al.  Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). , 2010, Antiviral research.

[21]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[22]  D. Katzenstein,et al.  Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.

[23]  S. Franceschi,et al.  Hodgkin lymphoma in the Swiss HIV Cohort Study. , 2009, Blood.

[24]  M. Battegay,et al.  Immunological recovery and antiretroviral therapy in HIV-1 infection. , 2006, The Lancet. Infectious diseases.

[25]  R. Bosch,et al.  Pretreatment Factors Associated With 3-Year (144-Week) Virologic and Immunologic Responses to Potent Antiretroviral Therapy , 2007, Journal of acquired immune deficiency syndromes.

[26]  Felipe García,et al.  Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count , 2004, Journal of acquired immune deficiency syndromes.

[27]  A. Antinori,et al.  Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI , 2011, BMC infectious diseases.

[28]  D. Richman,et al.  Baseline Predictors of CD4 T‐Lymphocyte Recovery With Combination Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[29]  C. Fraser,et al.  CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater , 2007, Journal of acquired immune deficiency syndromes.

[30]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[31]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[32]  Richard D Moore,et al.  CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  A. d’Arminio Monforte,et al.  Response to combination antiretroviral therapy: variation by age , 2008, AIDS.

[34]  J. Ilonen,et al.  Low CD4/CD8 T lymphocyte ratio in acute myocardial infarction , 1991, Clinical and experimental immunology.

[35]  A. Kelleher,et al.  Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. , 2009, AIDS research and human retroviruses.

[36]  J. Montaner,et al.  Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in Mexico , 2010, Journal of acquired immune deficiency syndromes.

[37]  G. Carcelain,et al.  CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3 , 2008, Antiviral therapy.

[38]  C. Speil.  Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment , 2009 .